Loading...
XNASAGIO
Market cap1.96bUSD
Jan 10, Last price  
34.42USD
1D
-4.12%
1Q
-19.30%
Jan 2017
-17.52%
IPO
23.90%
Name

Agios Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:AGIO chart
P/E
—
P/S
73.18
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-0.62%
Rev. gr., 5y
-22.25%
Revenues
27m
+88.36%
21,837,00025,106,00025,548,00065,358,00059,119,00069,892,00043,011,00094,387,000117,912,000203,196,000014,240,00026,823,000
Net income
-352m
L+372.25%
-23,706,000-20,102,000-39,407,000-53,504,000-117,732,000-198,471,000-314,670,000-346,028,000-396,611,000-335,218,0001,604,715,000-74,555,000-352,088,000
CFO
-296m
L-4.34%
-15,219,000-49,548,000-56,400,000-59,353,000-76,949,00038,562,000-285,232,000-304,421,000-370,622,000-290,759,000-407,320,000-309,478,000-296,062,000
Earnings
Feb 13, 2025

Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
URL
https://www.agios.com/
IPO date
Jul 24, 2013
Employees
389
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
26,823
88.36%
14,240
 
Cost of revenue
298,407
281,614
Unusual Expense (Income)
NOPBT
(271,584)
(267,374)
NOPBT Margin
Operating Taxes
(157,246)
Tax Rate
NOPAT
(271,584)
(110,128)
Net income
(352,088)
372.25%
(74,555)
-104.65%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,433
2,681
BB yield
-0.44%
-0.17%
Debt
Debt current
30,016
13,663
Long-term debt
185,972
157,655
Deferred revenue
Other long-term liabilities
(55,832)
3,279
Net debt
(590,375)
(1,239,549)
Cash flow
Cash from operating activities
(296,062)
(309,478)
CAPEX
(999)
(4,881)
Cash from investing activities
239,575
243,261
Cash from financing activities
5,433
2,350
FCF
(271,540)
(94,701)
Balance
Cash
776,928
1,096,993
Long term investments
29,435
313,874
Excess cash
805,022
1,410,155
Stockholders' equity
(823,018)
(483,025)
Invested Capital
1,722,197
1,672,777
ROIC
ROCE
EV
Common stock shares outstanding
55,651
54,789
Price
22.27
-20.69%
28.08
-14.57%
Market cap
1,239,359
-19.44%
1,538,487
-22.57%
EV
648,984
298,938
EBITDA
(264,961)
(258,810)
EV/EBITDA
Interest
12,793
Interest/NOPBT